期刊
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
卷 65, 期 2, 页码 304-312出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2010.05.042
关键词
basal cell carcinoma; case-control study; nonmelanoma skin cancer; nonsteroidal anti-inflammatory drug; p53; PTCH; squamous cell carcinoma
类别
资金
- National Institutes of Health, National Cancer Institute [CA118443, CA57494]
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Background: Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are potentially chemopreventive. Objective: We examined the relation between NSAID use and nonmelanoma skin cancer in a population-based case-control study. Methods: NSAID and analgesic use was analyzed in 1484 participants: 535 with squamous cell carcinoma (SCC), 487 with basal cell carcinoma (BCC), and 462 control subjects. Results: use of NSAIDs, particularly aspirin, was associated with a reduced odds ratio (OR) of SCC, especially tumors positive for p53 (OR 0.29; 95% confidence interval 0.11-0.79) or with PTCH loss of heterozygosity (OR 0.35; 95% confidence interval 0.13-0.96). Although not considered a NSAID, decreased ORs of both basal cell carcinoma and SCC were observed in relation to use of paracetamol (acetaminophen). Risk of BCC was unrelated to NSAID use. Limitations: Self-reported drug use was a limitation. Conclusions: This study supports the hypothesis that NSAIDs, aspirin in particular, may reduce risk of SCC and may affect specific molecular subtypes of SCC. (J Am Acad Dermatol 2011;65:304-12.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据